Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11087844 | 0.84 | — | — | |
| SCHEMBL11617678 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL11754477 | 0.77 | MAPT (0.31) | — | |
| SCHEMBL8813561 | 0.77 | GAA (0.42) | — | |
| SCHEMBL7810661 | 0.74 | — | — | |
| SCHEMBL11347719 | 0.74 | — | — | |
| SCHEMBL5182829 | 0.74 | TSHR (0.38) | CYP2C19 | |
| SCHEMBL11859496 | 0.71 | MAPT (0.31) | — | |
| SCHEMBL7812152 | 0.71 | ALDH1A1 (0.34) | — | |
| SCHEMBL8411619 | 0.71 | SMN1; SMN2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | MARTON MILANKOVITS | 2009-05-14 | — | — | US | disclosed |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | MILANKOVITS MARTON | 2009-03-19 | — | — | US | disclosed |
| US-20050208152-A1 | Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications | MILANKOVITS MARTON | 2005-09-22 | — | — | US | disclosed |
| US-4065567-A | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds | AMERICAN CYANAMID COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3991200-A | Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds | AMERICAN CYANAMID COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
| US-3952007-A | Processes for preparing 5-nitro-1-methyl-2-(2-dialkylaminovinyl)-imidazole and 5-nitro-1-methyl-2-imidazolyl carboxaldehyde | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | SOD1, OAT, ELANE | CYP2C19 2686/4885PDE4A 2685/4885PDE4C 2717/4885 |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | DHFR, FPGS, FOLR1 | CYP2C19 197/4885PDE4A 823/4885PDE4C 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.